Alto Neuroscience (ANRO) Change in Cash (2023 - 2026)

Alto Neuroscience has reported Change in Cash for 4 years, with the latest figure at $87.3 million in Q1 2026.

• Quarterly Change in Cash rose 1267.6% year-over-year to $87.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.0 million (up 330.75% YoY) and the FY2025 annual result came in at $8.3 million, down 90.42% from the prior year.
• Change in Cash advanced to $87.3 million in Q1 2026 per ANRO's latest filing, from $38.7 million in the prior quarter.
• Over five years, Change in Cash peaked at $123.3 million in Q1 2024 and troughed at -$13.5 million in Q4 2024.
• A 4-year average of $16.6 million and a median of -$7.5 million in 2025 frame the typical range for Change in Cash.
• The sharpest annual moves came in 2024 and 2026: Change in Cash sank 143.1% in 2024, then soared 1267.6% in 2026.
• Over 4 years, Change in Cash stood at $31.3 million in 2023, then slumped by 143.1% to -$13.5 million in 2024, then soared by 387.02% to $38.7 million in 2025, then soared by 125.71% to $87.3 million in 2026.
• According to Business Quant data, Change in Cash over the past three periods registered $87.3 million, $38.7 million, and -$9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.